Nina Babel
From Wikipedia, the free encyclopedia
Nina Babel is a German physician and scientist. As a professor at Ruhr University Bochum and Charité, she treats patients and performs research in the field of immunodeficiencies and kidney diseases.
Babel is the head of a research group focusing on immunology at the Charité.[1] At Ruhr University Bochum, she heads the Center for Translational Medicine with a focus on immunology and transplantation at Marien Hospital Herne.[2][3]
She studied medicine at Humboldt University of Berlin and completed her clinical training in the field of internal medicine, nephrology, and immunology at the Charité, where she also obtained her habilitation in 2008.[4] As a Rahel Hirsch habilitation grant recipient, she carried out most of her habilitation work at the Charité and, from 2006 to 2007, as a fellow at the Taussig Cancer Center, Cleveland Clinic (Ohio).[5][6]
Research and patient care
Babel's laboratory investigates mechanisms underlying the immunopathogenesis of viral diseases and develops new parameters and technologies to monitor the individual immune response and the risk of viral infection and virus-associated complications in immunocompromised patients.[4]
Babel has led several research projects focusing on the host's immune response to SARS-CoV-2. For instance, the researchers discovered that individuals who had a severe course of COVID-19 did not exhibit a diminished immune response in comparison to those who had a mild course of the disease.[7] In another study, it was observed that the development of antibodies after vaccination was lower with immunosuppressants than without, while the cellular immune response was preserved. According to this, patients can benefit from the vaccination despite their immunosuppressive therapy.[8] Babel continues to work on the topics of Sars-CoV-2 immunity, and in particular Long Covid and chronic fatigue.[9][10] Furthermore, her research topic includes analysis of interaction between host's immune response and herpes viruses such as Epstein–Barr virus.[11]
Babel has been coordinator and principal investigator of several DFG[12] and BMBF projects.[13][14] She has an h-index of 53, has been involved in over 300 scientific publications,[15][16] and is editor-in-chief for the Immunosuppression section of the journal Frontiers of Transplantation.[17]
Young researchers support programs
Babel works on programs to support young researchers. After serving as co-spokesperson of the SFB 650 Research Training Group at Charité from 2012 to 2016, she continued her work at Ruhr University Bochum, where she leads the RIMUR Research Training Group.[18][19] She also leads the Clinician Scientist Program at Ruhr University Bochum, for which she received funding from the DFG in summer 2022.[20][21]
